Drugs.com - Clinical Trials

Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)

Cellectar Granted U.S. FDA Breakthrough Therapy Designa...

Jun 5, 2025 0

FLORHAM PARK, N.J., June 04, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc...

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)

Lyra Therapeutics Reports Positive Results from the ENL...

Jun 4, 2025 0

WATERTOWN, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nas...

Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy

Vera Therapeutics Announces Atacicept Achieved 46% Prot...

Jun 3, 2025 0

BRISBANE, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nas...

Rilzabrutinib Granted Orphan Drug Designation in the US for Sickle Cell Disease

Rilzabrutinib Granted Orphan Drug Designation in the US...

Jun 3, 2025 0

Paris, June 3, 2025. The US Food and Drug Administration (FDA) has granted orpha...

Early Results from Johnson & Johnson’s Trispecific Antibody JNJ-5322 Show Promising Response in Heavily Pretreated Multiple Myeloma Patients

Early Results from Johnson & Johnson’s Trispecific Anti...

Jun 3, 2025 0

Chicago (June 3, 2025) – Johnson & Johnson announced today initial Phase 1 resul...

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

ImmunityBio Receives FDA Expanded Access Authorization ...

Jun 3, 2025 0

CULVER CITY, Calif.–(BUSINESS WIRE)–Jun. 2, 2025– ImmunityBio, Inc. (NASDAQ: IBR...

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

uniQure Provides Regulatory Update on AMT-130 for Hunti...

Jun 3, 2025 0

LEXINGTON, Mass. and AMSTERDAM, June 02, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (...

Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis

Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Des...

Jun 3, 2025 0

CAMBRIDGE, Mass.--(BUSINESS WIRE) June 03, 2025 -- Amylyx Pharmaceuticals, Inc. ...

Pheast Therapeutics Receives FDA Fast Track Designation for PHST001 for the Treatment of Ovarian Cancer

Pheast Therapeutics Receives FDA Fast Track Designation...

Jun 3, 2025 0

Redwood City, Calif., June 3, 2025 – Pheast Therapeutics, a clinical-stage biote...

Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor, Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C Mutations

Merck Announces MK-1084, an Investigational KRAS G12C I...

Jun 3, 2025 0

RAHWAY, N.J.--(BUSINESS WIRE) May 30, 2025 -- Merck (NYSE: MRK), known as MSD ou...

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

Arvinas and Pfizer's Vepdegestrant Significantly Improv...

Jun 3, 2025 0

NEW HAVEN, Conn. and NEW YORK, May 31, 2025 – Arvinas, Inc. (Nasdaq: ARVN) and P...

PIVOT-PO Phase III Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

PIVOT-PO Phase III Study for Tebipenem HBr Stopped Earl...

Jun 3, 2025 0

May 28 2025 -- GSK plc (LSE/NYSE: GSK) and Spero Therapeutics today announced th...

Elinzanetant Significantly Reduces Frequency of Moderate to Severe Vasomotor Symptoms Associated with Endocrine Therapy for Breast Cancer in Phase III OASIS-4 Study

Elinzanetant Significantly Reduces Frequency of Moderat...

Jun 3, 2025 0

Berlin, June 2, 2025 – Detailed results from the Phase III OASIS-4 study found t...

Johnson & Johnson Unveils First-in-Human Results for Pasritamig, Showing Early Anti-Tumor Activity in Prostate Cancer

Johnson & Johnson Unveils First-in-Human Results for Pa...

Jun 3, 2025 0

CHICAGO, JUNE 1, 2025 – Johnson & Johnson announced today new data from a Phase ...

$Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL in Phase 2 Portion of waveLINE-003 Trial$

Merck’s Investigational Zilovertamab Vedotin at 1.75 mg...

Jun 3, 2025 0

RAHWAY, N.J.--(BUSINESS WIRE) May 30, 2025 -- Merck (NYSE: MRK), known as MSD ou...

Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials

Itepekimab Met Primary Endpoint in One of Two Chronic O...

May 31, 2025 0

TARRYTOWN, N.Y. and PARIS, May 30, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceut...

Genentech’s Fenebrutinib Maintains Near-Complete Suppression of Disease Activity and Disability Progression for up to Two Years in People With Relapsing Multiple Sclerosis

Genentech’s Fenebrutinib Maintains Near-Complete Suppre...

May 31, 2025 0

South San Francisco, CA -- May 29, 2025 -- Genentech, a member of the Roche Grou...

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST - Modifier Gene Therapy for the Treatment of Stargardt Disease

Ocugen Announces Rare Pediatric Disease Designation Gra...

May 30, 2025 0

MALVERN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Compa...

Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease

Rocket Pharmaceuticals Provides Update on Phase 2 Clini...

May 30, 2025 0

CRANBURY, N.J.--(BUSINESS WIRE)--May 27, 2025-- Rocket Pharmaceuticals, Inc. (NA...

Teva Celiac Disease Candidate TEV-53408 Granted Fast Track Designation by US FDA

Teva Celiac Disease Candidate TEV-53408 Granted Fast Tr...

May 30, 2025 0

TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industrie...

Experimental Drug Development Centre Granted U.S. FDA Fast Track Designation for Antibody-Drug Conjugate EBC-129 to Treat Pancreatic Ductal Adenocarcinoma

Experimental Drug Development Centre Granted U.S. FDA F...

May 30, 2025 0

Singapore, 28 May 2025 – The Experimental Drug Development Centre (EDDC), Singap...

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for...

May 28, 2025 0

DUBLIN--(BUSINESS WIRE) May 23, 2025 --Prothena Corporation plc (NASDAQ:PRTA) to...

Phase 3 Clinical Study of Mazdutide in Chinese Adults with Overweight or Obesity (GLORY-1) Published in The New England Journal of Medicine (NEJM)

Phase 3 Clinical Study of Mazdutide in Chinese Adults w...

May 26, 2025 0

SAN FRANCISCO, U.S., SUZHOU, China May 26, 2025 – Innovent Biologics, Inc. (“Inn...

Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Presented New Data From Pivotal Phase 3 IMPALA-2...

May 26, 2025 0

LANGHORNE, Pa.--(BUSINESS WIRE) May 18, 2025 -- Savara Inc. (Nasdaq: SVRA) (the ...

1
2
3

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.